BNTA

CAS No. 685119-25-9

BNTA( —— )

Catalog No. M35227 CAS No. 685119-25-9

BNTA is a potent extracellular matrix (ECM) modulator. In a rat model of arthritis, BNTA modulates arthritis by promoting the synthesis of cartilage structural molecules on chondrocytes through the induction of superoxide dismutase 3 (SOD3) and regulating chondrogenesis through superoxide anion elimination.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 128 Get Quote
5MG 188 Get Quote
10MG 312 Get Quote
25MG 586 Get Quote
50MG 821 Get Quote
100MG 1098 Get Quote
500MG 2205 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BNTA
  • Note
    Research use only, not for human use.
  • Brief Description
    BNTA is a potent extracellular matrix (ECM) modulator. In a rat model of arthritis, BNTA modulates arthritis by promoting the synthesis of cartilage structural molecules on chondrocytes through the induction of superoxide dismutase 3 (SOD3) and regulating chondrogenesis through superoxide anion elimination.
  • Description
    BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation.
  • In Vitro
    BNTA (0.01-10?μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes.BNTA (0.1 μM; 2 d) increases SOX9 protein markedly.BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes.BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells.BNTA (0.01-10?μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes.BNTA (0.01-10?μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1?μM in IL1β-induced rat OA chondrocytes.BNTA (0.01-1?μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants.Cell Viability Assay Cell Line:Human OA chondrocytes Concentration:0.01, 0.1, 1, 10 μM Incubation Time:1, 3, 5, 7 d Result:No toxicity was observed.Western Blot Analysis Cell Line:Human OA chondrocytes Concentration:0.1 μM Incubation Time:2 d Result:Elevated SOX9 protein compared with vehicle.
  • In Vivo
    BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.Animal Model:Male SD rats weighing 80?g are induced by ACLT Dosage:0.015, 0.15, 1.5 mg/kg Administration:Intra-articular injection; twice a week for 4 and 8 weeks Result:Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Reactive Oxygen Species
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    685119-25-9
  • Formula Weight
    456.76
  • Molecular Formula
    C17H11BrClNO3S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (218.93 mM; Ultrasonic )
  • SMILES
    Clc1ccccc1C(=O)Nc1c(Br)scc1S(=O)(=O)c1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shi Y, et, al. A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development. Nat Commun. 2019 Apr 23; 10(1): 1914.?
molnova catalog
related products
  • BMS986260

    BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). BMS-986260?demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.?

  • X-alpha-Gal

    X-alpha-Gal is a substrate for alpha-galactosidase. It is used for differentiating alpha-galactosidase-positive strains of yeast.

  • TK216

    TK216 is a potent inhibitor of E26 transformation-specific (ETS) with anticancer activity.In DLBCL cell lines, TK216 (500 nM; for 24-72 hours) induces apoptosis.